Search Results - parkinson%27s+disease

8 Results

Sort By:

Methylene Blue and Methylene Violet Analogs as Mitochondrial Therapeutic Agents

Mitochondrial dysfunction has been implicated in a number of diseases, including Alzheimer’s disease (AD), movement disorders, diseases of the cardiovascular system, cancer, diabetes, blindness and deafness. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Membrane-penetrating...

Published: 1/25/2024 | Inventor(s): Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Indrajit Bandyopadhyay

Keywords(s): Alzheimer's Disease, Diabetes, Genetic Disorders, Metabolic Disorders, Mitochondrial medicine, Neurodegenerative Disorders, Parkinson's Disease, Pharmaceutical

Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals

Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes

Abstract: The National Institute on Drug Abuse (NIDA) is seeking interested parties to license or co-develop GDNFOS peptides and non-coding RNAs as therapeutic agents for neurodegenerative diseases. Glial cell line-derived neurotrophic factor (GDNF) is a small human protein encoded by the GDNF gene. GDNF has been effective therapy in laboratory animal...

Published: 4/8/2024 | Inventor(s): Qing Rong Liu

Keywords(s): ALS, GDNFOS3., Glial Cell Line Derived Neurotrophic Factor (GDNF), Multiple sclerosis, Parkinson's Disease

Category(s): TherapeuticArea > Neurology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration

Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies

Gaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Steven Rogers, Frank Schoenen, Juan Marugan

Keywords(s): CHAPERONES, Gaucher Disease, GLUCOCEREBROSIDASE, IBXXXX, NB1BXX, NBXXXX, NON-INHIBITORY, Parkinson's Disease, proteinopathy, UAXXXX, VEXXXX, WKXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Rare / Neglected Diseases

The preparation of a brain targeted artificial nano-enzyme and application

Reference #: 01514 The University of South Carolina is offering licensing opportunities for The preparation of a brain targeted artificial nano-enzyme and application Background: Chronic neuroinflammation is caused by the activation of microglia, which is the major cause of central neuronal system (CNS) diseases, including Alzheimer’s disease,...

Published: 4/25/2024 | Inventor(s): Peisheng Xu, Haijun Liu

Keywords(s): Alzheimer’s disease, Amyotrophic lateral sclerosis, brain injury, Brain targeted nanoparticle, Brain tumor, Epilepsy, frontotemporal dementia, glioblastoma, Huntington's disease, Multiple sclerosis, neonatal hypoxic-ischemic, neuroblastoma, Parkinson's disease, post-traumatic stress disorder, Spinal cord injury, stroke

Category(s): Nanotechnology, Health Sciences, Biomedical and Life Sciences

Compounds to Modulate Retinoid X Receptors

The human retinoid X receptors (RXRs) function as transcriptional regulators, often in partnership with members of a larger nuclear receptor family of transcription factors. RXR agonists have been shown to modulate RXR transcription and activate or repress various biological pathways and effect therapeutic results for various conditions. There are a...

Published: 2/23/2023 | Inventor(s): Carl Wagner, Peter Jurutka, Pamela Marshall

Keywords(s): Cancer, Diabetes, Parkinson's Disease

Category(s): Cancer Therapeutics, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Pharmaceuticals

Compounds to Modulate Retinoid X Receptors

Published: 2/23/2023 | Inventor(s): Carl Wagner, Pamela Marshall, Peter Jurutka

Keywords(s): Cancer, Diabetes, Parkinson's Disease

Category(s): Cancer Therapeutics, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Pharmaceuticals

Therapeutic Compounds to Enhance Cognition, Counteract Depression and Treat Smoking Addiction

Chemicals Selectively Modulate Cell Receptors Linked to Neurological Disorders in Humans and Other MammalsThese compounds enable effective treatment of neurological disorders involving cognitive deficits (including Alzheimer’s and Parkinson’s diseases), depression and drug dependences such as tobacco (nicotine) and betel nut addictions....

Published: 6/27/2021 | Inventor(s): William Kem, Ferenc Soti, Hong Xing

Keywords(s): Alzheimer's Disease, Anti-Inflammatory, Cognition Enhancer, Dementia, Parkinson's Disease, Post Traumatic Stress Disorder, Schizophrenia, Wound Healing

Category(s): Technology Classifications > Human Health Care > Therapeutics

Noninvasive Biomarker to Measure the Progression of Parkinson’s Disease

Improves Clinical Trials and Potential of Therapeutic Treatments for Parkinson’s DiseaseThis noninvasive imaging biomarker uses free-water levels revealed in MRI scans of the brain to indicate the progression of Parkinson’s disease in a patient. Parkinson’s disease is a chronic and progressive movement disorder of the nervous system;...

Published: 6/27/2021 | Inventor(s): David Vaillancourt

Keywords(s): Biomarker, diffusion imaging, disease progression, Imaging, Parkinson's Disease

Category(s): Technology Classifications > Medical Devices > Others